Recital 4, Decision_act (EU) 2021/2014

In forcesince 17 Nov 2021

On 4 October 2021, the European Medicines Agency’s Committee for Medicinal Products for Human Use concluded that an extra dose of the COVID-19 vaccines Comirnaty and Spikevax may be given to people with severely weakened immune systems, at least 28 days after their second dose [https://www.ema.europa.eu/en/news/comirnaty-spikevax-ema-recommendations-extra-doses-boosters]. The Committee also evaluated data for Comirnaty showing a rise in antibody levels when a booster dose is given approximately 6 months after the second dose in people from 18 to 55 years old. On the basis of this data, the Committee concluded that booster doses for Comirnaty may be considered at least 6 months after the second dose for people aged 18 years and older. As stated by the European Medicines Agency, public health bodies at national level may issue official recommendations on the use of booster doses, taking into account emerging effectiveness data and the limited safety data. The product information of Comirnaty [https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product-information_en.pdf] and Spikevax [https://www.ema.europa.eu/en/documents/product-information/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_en.pdf] have been updated accordingly to include these recommendations.